<DOC>
	<DOCNO>NCT01894984</DOCNO>
	<brief_summary>The purpose study evaluate long-term treatment efficacy , safety risperidone long-acting injection participant schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) .</brief_summary>
	<brief_title>An Observational Study Evaluate Efficacy Safety Risperidone Long-Acting Injection Treatment Schizophrenia</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multi-center ( conducted one center ) , prospective ( study follow participant forward time ) observational study risperidone long-acting injection participant schizophrenia . The study consist 2 part : Screening ( , 28 day study commences Day 1 ) Treatment ( , Week 1-24 ) . All eligible participant ( risperidone intolerance test screening ) receive risperidone intramuscular injection ( injection substance muscle ) dose , either 25 milligram ( mg ) , 37.5 mg 50 mg every two week . Efficacy participant primarily evaluate Positive Negative Syndrome Scale . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>Male female , age 1865 year Participant must meet diagnostic criterion schizophrenia schizophreniform disorder accord Diagnostic Statistical Manual Mental Disorders , fourth edition ( DSMIV ) TM Total course disease 5 year According physician 's discretion , participant need change risperidone longacting injection atypical antipsychotic drug Participant legally acceptable representative must sign informed consent document indicate understand purpose procedure require study willing participate study Significant risk suicidal violent behavior , clinically assess Investigator Have aggressive behavior excite , restless History current symptom tardive dyskinesia ; neuroleptic malignant syndrome ; evidence dysfunction liver kidney severe physical disease ; severe , lifethreatening allergic reaction drug Known hypersensitivity risperidone Female participant pregnant breastfeeding planning become pregnant study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Risperdal Consta</keyword>
	<keyword>Oral antipsychotic</keyword>
</DOC>